A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 years and above, with pulmonary arterial hypertension (PAH)

Registry ID

EUCTR2006-001464-23

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ

Start date

2006-06-08

Completion date

2013-08-20

Last update

2026-08-16

Conditions

• Pulmonary Arterial Hypertension PAH .
• Pulmonary Arterial Hypertension

Summary

To assess the effect on exercise capacity (as measured by the 6 Minute Walk Distance) after 12 weeks of treatment of sildenafil (20mg TID) or placebo when added to subjects with PAH who are stabilized on bosentan therapy

Locations

• , , Italy
• , , UK
• , , Germany
• , , Czechia
• , , Greece

Related clinical trials

• Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
• Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
• Xenon MRI Pulm Hypertension
• DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
• A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

View on source registry